A Phase 2 interventional study of Bevacizumab and Docetaxel in Breast Cancer, sponsored by Sanofi. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-23.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies testing bevacizumab in Breast Neoplasms — 9 open to participants now, 10 under way, none of them phase 3. Bevacizumab · Breast Neoplasms.
Among the 131 studies testing bevacizumab in Breast Neoplasms, this one is the 56th largest by enrollment of the 130 interventional ones that give a count, is one of 13 that started in 2006, is one of 89 in phase 2, and was the 25th registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →9 of the 131 studies testing bevacizumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–70 · Women only
Yukinori Ozaki · Sites in Japan
Ages 18+
Tongji Hospital · Sites in China
Ages 18+
Lebanese University · Sites in Lebanon
Ages 18+
Henan Cancer Hospital · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 96 · Phase 3 19 · Phase 4 4
First in 2000; this study’s year is marked. 13 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is close to the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 58 across the 130 interventional studies. Of the 106 that completed or were terminated, 59 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 131 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
40 studies in Breast Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 39 finished, 14 (36%) have results posted.
Among the 40 studies in Breast Neoplasms by Sanofi, this one is the 20th largest by enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2006, is one of 21 in phase 2, and was the 10th registered.
Sanofi’s Breast Neoplasms studies by the year they started, since 1994.
3 of the studies testing bevacizumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05398861Henan Cancer HospitalUtidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer | 2026-12-30 |
| NCT07359404YING FANSacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC | 2026-12-31 |
| NCT07150208Fudan UniversityT-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 131 studies testing bevacizumab in Breast Neoplasms, from their registry updates:
Among Sanofi’s 40 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Pilot, phase II, parallel-group, open-label, noncomparative, prospective, multicenter study designed to evaluate the progression-free survival of docetaxel and bevacizumab ± trastuzumab for the first-line treatment of participants with metastatic breast cancer. Participants were stratified according to human epidermal growth factor receptor-2 (HER2) status at the time of enrollment. HER2 negative participants were assigned to receive docetaxel and bevacizumab (DB). HER2 positive participants were assigned to receive docetaxel, bevacizumab, and trastuzumab (DBT).
All participants (except one) were off study treatment on 30 June 2011. All efficacy analysis and safety analysis was performed using the cut-off date of June 2011. One participant continued treatment till 11 March 2012. For this participant, adverse events were collected upto 19 April 2012 and included in the safety analysis.
The study included:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following information on clinical trials is provided for information purposes only to allow participants and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.
INCLUSION CRITERIA:
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stratum 1: HER2 Negative participants with metastatic breast cancer treated with DB (docetaxel and bevacizumab) intravenously (IV) every 3 weeks (q3w) until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
Drug: Bevacizumab · Drug: Docetaxel
Stratum 2: HER2 Positive participants with metastatic breast cancer treated with DBT (docetaxel, bevacizumab, and trastuzumab) IV q3w until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
Drug: Bevacizumab · Drug: Docetaxel · Drug: Trastuzumab
Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on * On Day 1 of the 1st cycle over 120 minutes * On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose * On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses * On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses
Also known as: Avastin
Docetaxel 75 mg/m\^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
* A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1. * For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion
Also known as: Herceptin
Progression-free Survival (PFS) Rate: Percentage of Participants With PFS
PFS was the time from registration to first documentation of * progressive disease (PD) based on Response Evaluation Criteria in Solid Tumors (RECIST) - criteria pre-defining changes in lesion size or appearance * symptomatic deterioration * death due to any cause (in absence of PD). The Percentage of participants with PFS is reported. For the analysis, participants were censored * on the last available tumor assessment date on study treatment if they * had no PFS event * were on anticancer therapy not related to study treatment * on the registration date if they * did not receive study drug * had no post baseline tumor assessment
Time frame: Up to 6 months and 12 months after treatment initiation
Time to Progression-free Survival (PFS)
Time to PFS was the interval from the date of registration to the earliest of the following documented dates: * PD as defined by RECIST (criteria pre-defining changes in lesion size or appearance) * symptomatic deterioration * death. Time to PFS was estimated from Kaplan-Meier Plots.
Time frame: From treatment initiation to PFS event (up to June 2011)
Confirmed Overall Response (OR) Based on RECIST Criteria
Confirmed OR was confirmed Complete Response (CR) + confirmed Partial Response (PR). According to RECIST * CR was the disappearance of all tumor lesions * PR was a pre-defined decrease in the size of tumor lesions. To determine a response, radiologic tumors assessments were performed using computed tomography (CT) and/or magnetic resonance imaging (MRI) of the chest, and the abdomen, bone scan or positron emission tomography (PET) scan, and other imaging techniques as clinically indicated. To confirm a response, 2 assessments separated by 28 days or more were required.
Time frame: From treatment initiation to June 2011
Number of Participants With Confirmed Clinical Benefit Based on RECIST Criteria
Clinical Benefit (CB) was achieved in participants with a response (CR + PR) or a stable disease (SD). According to RECIST * CR was the disappearance of all tumor lesions * PR was a pre-defined decrease in the size of tumor lesions * SD was neither sufficient decrease in tumor size to qualify for PR or sufficient increase to qualify for PD. Confirmation of a response needed 2 responses scored, separated by 28 days or more (for CR and PR), and by 26 weeks or more (for SD).
Time frame: From treatment initiation to June 2011
Duration of Response (DR)
DR was the interval from date of initial documented confirmed response (CR or PR) to the first documented confirmed date of disease progression (PD) or death from any cause in the absence of previous documentation of objective tumor progression. Participants who were alive and without any record of PD at the time of discontinuation were censored at the last available tumor assessment date; participants with non-study anti-cancer therapy during the study were censored at the last available tumor assessment date prior to the anti-cancer therapy. DR was estimated from Kaplan-Meier Plots.
Time frame: From treatment initiation to June 2011
Overall Survival (OS) Time
OS was the interval between the date of study entry and the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. OS time was estimated from Kaplan-Meier Plots.
Time frame: From treatment initiation to June 2011
Number of Participants With Adverse Events (AE)
An adverse event (AE) was any unfavorable and unintended sign, symptom, syndrome, or illness that developed or worsened during the clinical study. AEs occurring on or after first dose of study medication inclusive to 30 days post-last dose were the treatment emergent adverse events (TEAEs). An serious adverse event was an AE that at any dose (including overdose) resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly, and/or was medically important.
Time frame: From treatment initiation to 30 days after the last dose of study treatment
| Milestone | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab |
|---|---|---|
| Started | 52 | 21 |
| Treated (saftey population) | 52 | 20 |
| Completed | 1 | 0 |
| Not completed | 51 | 21 |
| Withdrew: Did not receive study medication | 0 | 1 |
| Withdrew: Adverse event | 7 | 4 |
| Withdrew: Participant's request | 3 | 4 |
| Withdrew: Disease progression | 38 | 8 |
| Withdrew: Investigator decision | 2 | 2 |
| Withdrew: Found ineligible | 1 | 0 |
| Withdrew: Presumed cr on study | 0 | 1 |
| Withdrew: Receiving liver ablation | 0 | 1 |
PFS was the time from registration to first documentation of * progressive disease (PD) based on Response Evaluation Criteria in Solid Tumors (RECIST) - criteria pre-defining changes in lesion size or appearance * symptomatic deterioration * death due to any cause (in absence of PD). The Percentage of participants with PFS is reported. For the analysis, participants were censored * on the last available tumor assessment date on study treatment if they * had no PFS event * were on anticancer therapy not related to study treatment * on the registration date if they * did not receive study drug * had no post baseline tumor assessment
| percentage of participants | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab |
|---|---|---|
| PFS rate at 6 months | 59.6 (45.1 to 73.0) | 90.5 (69.6 to 98.8) |
| PFS rate at 12 months | 30.8 (18.7 to 45.1) | 81.0 (58.1 to 94.6) |
Time to PFS was the interval from the date of registration to the earliest of the following documented dates: * PD as defined by RECIST (criteria pre-defining changes in lesion size or appearance) * symptomatic deterioration * death. Time to PFS was estimated from Kaplan-Meier Plots.
| days | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab |
|---|---|---|
| Time to Progression-free Survival (PFS) | 255 (158 to 315) | 403 (363 to 1078) |
Confirmed OR was confirmed Complete Response (CR) + confirmed Partial Response (PR). According to RECIST * CR was the disappearance of all tumor lesions * PR was a pre-defined decrease in the size of tumor lesions. To determine a response, radiologic tumors assessments were performed using computed tomography (CT) and/or magnetic resonance imaging (MRI) of the chest, and the abdomen, bone scan or positron emission tomography (PET) scan, and other imaging techniques as clinically indicated. To confirm a response, 2 assessments separated by 28 days or more were required.
| participants | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab |
|---|---|---|
| Confirmed overall response | 30 | 17 |
| Confirmed complete response | 3 | 4 |
| Confirmed partial response | 27 | 13 |
Clinical Benefit (CB) was achieved in participants with a response (CR + PR) or a stable disease (SD). According to RECIST * CR was the disappearance of all tumor lesions * PR was a pre-defined decrease in the size of tumor lesions * SD was neither sufficient decrease in tumor size to qualify for PR or sufficient increase to qualify for PD. Confirmation of a response needed 2 responses scored, separated by 28 days or more (for CR and PR), and by 26 weeks or more (for SD).
| participants | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab |
|---|---|---|
| with confirmed Clinical Benefit (CR+PR+SD) | 35 | 17 |
| with confirmed CR | 3 | 4 |
| with confirmed PR | 27 | 13 |
| with confirmed SD | 14 | 1 |
DR was the interval from date of initial documented confirmed response (CR or PR) to the first documented confirmed date of disease progression (PD) or death from any cause in the absence of previous documentation of objective tumor progression. Participants who were alive and without any record of PD at the time of discontinuation were censored at the last available tumor assessment date; participants with non-study anti-cancer therapy during the study were censored at the last available tumor assessment date prior to the anti-cancer therapy. DR was estimated from Kaplan-Meier Plots.
| days | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab |
|---|---|---|
| Duration of Response (DR) | 232 (126 to 305) | 366 (293 to 859) |
OS was the interval between the date of study entry and the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. OS time was estimated from Kaplan-Meier Plots.
| days | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab |
|---|---|---|
| Overall Survival (OS) Time | 750 (362 to 1159) | 986 (619 to 1705) |
An adverse event (AE) was any unfavorable and unintended sign, symptom, syndrome, or illness that developed or worsened during the clinical study. AEs occurring on or after first dose of study medication inclusive to 30 days post-last dose were the treatment emergent adverse events (TEAEs). An serious adverse event was an AE that at any dose (including overdose) resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly, and/or was medically important.
| participants | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab |
|---|---|---|
| with treatment emergent adverse events (TEAEs) | 52 | 20 |
| with serious adverse events | 14 | 4 |
| with TEAEs resulting in death | 3 | 0 |
Collected over From treatment initiation up to 30 days following the last dose of study medication (upto April 2012). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Docetaxel and Bevacizumab | — | 14/52 (26.9%) | 52/52 (100%) |
| Docetaxel, Bevacizumab and Trastuzumab | — | 4/20 (20%) | 20/20 (100%) |
| Event | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab |
|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/52 | 1/20 |
| Atrial fibrillationCardiac disorders | 0/52 | 1/20 |
| Abdominal painGastrointestinal disorders | 0/52 | 1/20 |
| Catheter site infectionInfections and infestations | 0/52 | 1/20 |
| Perirectal abscessInfections and infestations | 0/52 | 1/20 |
| PneumoniaInfections and infestations | 0/52 | 1/20 |
| DehydrationMetabolism and nutrition disorders | 1/52 | 1/20 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/52 | 0/20 |
| TachycardiaCardiac disorders | 1/52 | 0/20 |
| Duodenal ulcerGastrointestinal disorders | 1/52 | 0/20 |
| Event | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 34/52 | 15/20 |
| FatigueGeneral disorders | 36/52 | 13/20 |
| NauseaGastrointestinal disorders | 28/52 | 10/20 |
| Lacrimation increasedEye disorders | 15/52 | 10/20 |
| HeadacheNervous system disorders | 16/52 | 9/20 |
| DiarrhoeaGastrointestinal disorders | 23/52 | 8/20 |
| DysgeusiaNervous system disorders | 20/52 | 8/20 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 17/52 | 8/20 |
| HypertensionVascular disorders | 7/52 | 8/20 |
| VomitingGastrointestinal disorders | 12/52 | 7/20 |
| Age Continuous(years) | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab | Total |
|---|---|---|---|
| Mean | 56.2 ± 10.78 | 52.8 ± 12.65 | 55.2 ± 11.37 |
| Age, Customized(participants) | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab | Total |
|---|---|---|---|
| <=65 years | 41 | 17 | 58 |
| Between 65 and 75 years | 8 | 3 | 11 |
| >=75 years | 3 | 1 | 4 |
| Sex: Female, Male(Participants) | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab | Total |
|---|---|---|---|
| Female | 52 | 21 | 73 |
| Male | 0 | 0 | 0 |
| Eastern Cooperative Oncology(participants) | Docetaxel and Bevacizumab | Docetaxel, Bevacizumab and Trastuzumab | Total |
|---|---|---|---|
| ECOG Performance Score is 0 | 28 | 16 | 44 |
| ECOG Performance Score is 1 | 24 | 5 | 29 |
The record gives a start of Aug 2006, a primary completion of Jun 2011 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Docetaxel